ASSUMPTION OF RISK: You acknowledge that these substances have not been sterilized or tested by the FDA for safety or efficacy
While results take time and multiple sessions are usually required, this treatment offers a precise approach to eliminating specific fat pockets without invasive surgery
Therefore, in consideration of the prior request discussed in FY 2022 rulemaking and to further explore this current finding, we examined claims data from the September 2022 update of the FY 2022 MedPAR file for MS-DRGs 246, 247, 248, and 249 for all other cases assigned to MS-DRGs 246, 247, 248, and 249 that did not report percutaneous coronary IVL as reflected in the previous table
12: Jzwiak M, Bauer M, Kamysz W, Kleczkowska P